Compare YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Zimmer Biomet Holdings Inc — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.02, while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: Zimmer Biomet Holdings Inc pays a 1.08% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals.
| QDTY | ZBH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $107.71 |
52-Week Low | $36.57 | $79.58 |
Market Cap | — | $17.20B |
Enterprise Value | — | $24.25B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTY trades at $39.53 with minimal daily movement (+0.15%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, while oscillators remain neutral. The stock faces immediate resistance at $40 and support at $39. Recent corporate actions include consistent weekly dividend distributions, with amounts ranging from $0.22 to $0.32 per share throughout 2026.
The outlook remains cautious given the bearish technical signals and lack of available fundamental data. While the consistent dividend payments provide some income stability, the absence of key financial metrics like P/E ratio and profitability measures limits fundamental analysis. Investors face uncertainty regarding the company's financial health and growth prospects without current earnings data.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
